An interventional study of Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G. in Diabetes Mellitus, Gestational Diabetes Mellitus (GDM) and Pre Diabetes, sponsored by Smartest Technologies. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Smartest Technologies · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diabetes, Gestational with a site in Israel — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Israel.
Among the 25 studies in Diabetes, Gestational with a site in Israel, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 24th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →6 of the 25 studies in Diabetes, Gestational with a site in Israel are open now. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only
Hadassah Medical Organization · Sites in Israel
Ages 18–45 · Women only
The Baruch Padeh Medical Center, Poriya · Sites in Israel
Ages 18+ · Women only
Hadassah Medical Organization · Sites in Israel
Ages 18–50 · Women only
HaEmek Medical Center, Israel · Sites in Israel
Ages 18–60 · Women only · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 142 across the 15 interventional studies, 150 across the 9 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Smartest Technologies as lead sponsor.
Smartest Technologies has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06355154Hadassah Medical OrganizationEffects of Moderate Carbohydrate Consumption on Metabolic and Obstetric Outcomes in Pregnant Women With Insulin-treated Diabetes- A Randomized Controlled Trial | 2027-05-01 |
| NCT07158970Wolfson Medical CenterHome-Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus (GDM) | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Diabetes, Gestational with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is conducted in Israel so plain language for the study is exist in Hebrew only
Protocol Title:
A Proof of Concept (PoC), Randomized, Controlled study to validate the algorithm and evaluate the accuracy, safety and pain level of the Smartest-AE in comparison to self-measure Blood Glucose Levels
Investigational Device:
The Smartest-AE
Device Description:
The Smartest's System is intended to measure blood glucose levels in home environment. The Smartest's System consists of a disposable single-use device and a mobile app.
At this study Smartest-AE ("Smartest-AE") will be tested.
Study Overview:
The subjects will be enrolled from the Diabetes Mellitus (DM) clinics in the hospitals, endocrinological clinic, Internal divisions, obstetrics and gynecology department, diabetes in pregnancy and maternal and fetal medicine clinics.
Study subjects will be consecutively screened and enrolled into the study. The study will include up to 300 subjects, men and women aged 18 to 80.
The trial will encompass two distinct populations:
Group 1- Diabetes Mellitus Patients At least 100 subjects who diagnosed with Type I/Type II DM or GDM (Gestational Diabetes Mellitus), who regularly prick their fingers to monitor blood glucose levels and willing to participate in the study, and
Group 2- High risk individuals. at least 100 individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to to one of the following various risk factors:
The study will be conducted in 2 stages:
Stage I- Algorithm verification- Blood glucose levels will be taken from the first 30 subjects in order to verify the algorithm. At the end of the enrollment of the first 30 cases an analysis will be done by Smartest's R\&D. If the algorithm yields correlation of R2>0.9, based on the calibration curves, the study will proceed to the second phase. In case the calibration does not show the expected R2 the Smartest's R\&D will re-assess the algorithm. If correction/ modification to the algorithm will be implemented another 30 subjects will be enrolled to verify the updated algorithm.
If the analysis following algorithm update, yields satisfying results (R2>0.9), the study will proceed to the second stage and the results of the 30 subjects used for verification will be included in the final analysis. If not, the study will be temporarily paused and the device algorithm will be re-assessed by Smartest's R\&D for accuracy and precision. Following that, another 30 subjects will be enrolled for algorithm verification. If the expected R2 is not obtained the study will be terminated.
Blood glucose levels will be measured for all 30/60/90 subjects using 2 devices:
The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
All Subjects will complete a Numeric Rating Scale (NRS) questionnaire (Appendix A) to determine their level of pain from each device. NRS will be completed following each finger's pricking
Following NRS completion, blood will be taken from the subject's veins for blood glucose level that will be measured by the site's local lab.
NRS will not be completed following blood taken from the vein.
Stage II- Following algorithm verification and Smartest's approval to continue to stage II at least 200 subjects will be recruited.
Blood Glucose levels will be taken from each subject using the 2 devices; the Smartest-AE and the commercial glucometer.
The blood levels' results of the Smartest-AE will be compared to the commercial approved glucometer in order to assess accuracy. Subjects' comfort/pain level will be assessed following each finger's pricking using the Numeric Rating Scale (NRS) questionnaire
All Subjects will complete the NRS questionnaire to determine their level of pain from each device.
Following NRS completion, blood will be taken from the subject's veins for blood glucose level that will be measured by the site's local lab.
NRS will not be completed following blood taken from the vein. No follow-up period is expected.
Fingers III (middle) and IV (ring) of the non-dominant hand, will be pricked. Randomization will be used to allocate subjects that will be first tested with the Smartest-AE device and subjects that will be first tested with the commercial device. Finger III will always be the first to be pricked.
It was decided that subject IDs' even numbers will have the first prick with the Smartest-AE and subject IDs' odd numbers will have the first prick with the commercial device at each of the groups (1 and 2).
In case the device shows 'error 'or the results seems objectively, to be unreasonable (for eg: extremely high or low blood glucose level result that does not reflect subject physical condition at the time of test), another attempt will be done to achieve the blood glucose level. If the error will be obtained in the first test, then NRS will be completed by the subject subsequently to the test and the second attempt will be done only after the second (reference device) test will be performed. Up to 2 attempts are allowed for each system. Subject that has measurement results only from one system will be excluded from the analysis.
In case failings will be occurred in the venous blood test (either during the blood taking (problematic veins, etc.) or error received from the lab (hemolytic blood, etc.)), a second attempt will not be done and the result will be indicated as missing.
Study Population:
Adults volunteers, men and women, at least 25% of each gender at each group, at the ages of 18- 80 years old, diagnosed with Type I/Type II DM or GDM (Gestational diabetes Mellitus), who regularly prick their fingers to monitor blood glucose levels (Group 1, Diabetes Mellitus patients) and High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to various risk factors (Group 2).
Hospital personnel are allowed to participate in this study as long they are not subjected directly to the principal investigator.
All subjects will confirm their willingness to participate in the study by signing an Informed Consent Form (ICF).
Study Objective:
To validate the algorithm and to evaluate the accuracy, safety and pain level of the Smartest-AE
Inclusion Criteria:
Diagnosed with either:
Group 2: High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to one of the following various risk factors:
Exclusion Criteria:
Study Duration :
One year depending on rate of subject recruitment. Duration for each participant: A single visit for couple of hours in the clinic or at the department during hospitalization.
Primary Endpoints:
Stage I- Smartest-AE system algorithm verification (R2>0.9) Stage II- Assess the accuracy of the Smartest-AE glucose measurements' results in comparison to the results received from a commercial approved glucometer.
Secondary Efficacy Endpoints:
Safety Endpoint:
Any adverse events reported throughout the study following finger pricking will be recorded, including severity (Adverse events such as: infection, exceptional bleeding, blisters, etc.)
Sample size:
The sample size was calculated based on the expected correlation between the commercial glucometer and the Smartest-AE using the G*Power software (version 3.1.9.6), focusing on the Pearson correlation coefficient. The following parameters were used:
Test Type: Exact, Correlation: Bivariate normal model. Tail(s): Two-tailed test. Effect Size (ρ H1): A correlation coefficient of 0.3, reflecting a realistic expectation of the correlation between the variables.
α Error Probability: The alpha level was set at 0.05, maintaining the standard criterion for statistical significance, where there is a 5% chance of a Type I error.
Power (1-β Error Probability): The power was set at 80% (0.8), indicating that there is an 80% probability of correctly rejecting the null hypothesis when it is false.
Correlation ρ H0: The null hypothesis correlation was set to 0, assuming no correlation between the variables.
The calculation results yielded a total sample size of 84 samples.
Smartest company received a grant from the Israel Innovation Authority (IIA). As part of the grant the IIA set a milestone of conducting a clinical trial in 200 subjects for this study purposes. Therefore, the study population size is higher than the necessary sample size.
Statistical Analysis:
Descriptive Statistics: Data will be described by group using mean, standard deviations, median, minimum, and maximum for continuous variables, and counts and proportions for categorical variables.
Subgroup Analysis Stratification by Experience: Differences in reported pain levels between experienced (Group 1) and naïve (Group 2) subjects will be tested using a regression analysis.
Gender Analysis: Differences in reported pain levels will be tested across gender, ensuring at least 25% representation from each gender in both groups.
Software and Data Management Software: All statistical analyses will be conducted using R software. R packages such as "ggplot2" for data visualization and "dplyr" for data manipulation will be utilized to handle and analyze the study data.
Data Management: Data will be coded and stored securely with access restricted to authorized personnel only.
Tables and Figures Table 1: Demographic and Baseline Characteristics by Group. Table 2: Summary Statistics of Blood Glucose Measurements from Smartest-AE, Commercial Glucometer, and Blood Tests.
Table 3: Subgroup Analysis of Pain Levels. Figure 1: correlation plot of Blood Glucose Measurements from Smartest-AE, Commercial Glucometer, and Blood Tests.
Figure 2: Raincloud plots of Pain Levels Reported on NRS by gender.
Handling of Missing Data Missing Data Policy: Subjects missing measurements from either the Smartest-AE or the commercial glucometer will be excluded from the analysis.
Data Imputation: No imputation will be performed for missing glucose measurements; only complete case analysis will be used.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
This study's planned enrollment of 300 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Browse Diabetes, Gestational studies →This is the only study on the registry with Smartest Technologies as lead sponsor.
Compared within Diabetes, Gestational, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with either:
Group 2: High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to one of the following various risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Smartest's System is intended to measure blood glucose levels in home environment. The Smartest's System consists of a disposable single-use device and a mobile app.
Device: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.
Device: Smartest-AE: The lancet that will be used will be the Vitrex Soft Lite lll 28G.
The lancet that will be used for all subjects will be the Vitrex Soft Lite lll 28G.
Algorithm verification
Stage I- Smartest-AE system algorithm verification (R2\>0.9)
Time frame: 1 months
Stage II- Accuracy
Stage II- Assess the accuracy of the Smartest-AE glucose measurements' results in comparison to the results received from a commercial approved glucometer.
Time frame: 3 months
Pain Level
Subjects' pain level of the Smartest-AE vs. the commercial lancet using the NRS questionnaire
Time frame: 4 months
accuracy vs. lab results
Assess the accuracy of the Smartest-AE glucose measurements' results and the commercial glucometer results in comparison to the blood glucose level results of the venous blood test received from the local site's lab
Time frame: 4 months
Safety
Any adverse events reported throughout the study following finger pricking will be recorded, including severity (Adverse events such as: infection, exceptional bleeding, blisters, etc.)
Time frame: 4 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2024; primary completion for Jan 2025, 4 months later.
Of 309 interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.